GlassScriptPhysician profile
Karen Gates
NPI 1922683028
$1,269.13
in general payments reported to CMS, 2019-2025
11 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $44.91 · 2023: $126 · 2024: $571 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761 · Travel and Lodging: $239 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $760.99 |
| Travel and Lodging | $238.70 |
| Education | $115.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $386.50 | 2024 | Interstim |
| Endo USA, INC. | $197.98 | 2025 | Xiaflex |
| Coloplast Corp | $184.42 | 2024 | |
| Astellas Pharma US INC | $120.65 | 2021-2023 | Myrbetriq |
| Boston Scientific Corporation | $113.06 | 2025 | General - Kidney Stone Disease |
| Janssen Biotech, INC. | $100.28 | 2021-2025 | Carvykti, Rybrevant |
| Clarus Therapeutics INC. | $61.85 | 2021 | |
| Procept Biorobotics Corporation | $37.96 | 2025 | |
| Pfizer INC. | $27.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.54 | 2021 | |
| Teleflex LLC | $17.29 | 2023 | Urolift |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Gates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.